ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Increasing Survival Through Adjuvant Therapy Seen As Adding To Cost Of Care

October 24, 1975

NSABP Disputed NCI Cost Estimate For P-4 Trial.

May 25, 2007

OMB Orders NCI to Cut 12 Percent Until Final budget Is Approved; Grants Being Renegotiated

December 4, 1981

Commission Urges Bypass Funding for Breast Cancer

November 5, 1993

Studies Link Age-Dependent Outcome To Immune Cells

November 28, 2003

In Brief: General Motors Cancer Prizes Awarded; Thomas Promoted; HIV Research funding

June 24, 1994